Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05196087 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Study acronym: NIP IT!
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Jun 2027 → Jun 2028
See other at-risk trials from University Health Network, Toronto

Record History

  1. Primary and study completion pushed from Jun 2027 to Jun 2028 Enrollment increased: 500 → 800 participants · Eligibility criteria expanded, about 4 words Show 2 more changesShow less
    • Enrollment increased: 500 → 800 participants
    • Eligibility criteria expanded, about 4 words
  2. Primary and study completion dates: Jun 2026 to Jun 2027v7
  3. Re-verified, no change to tracked fieldsv6
  4. Site contact updatedv5
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 2022 to Jul 20, 2022 · Site details revisedv4 Show 2 more changesShow less
    • Start date changed from estimate of Jun 2022 to Jul 20, 2022
    • Site details revised
Show 2 earlier versionsHide 2 earlier versions
  1. Primary and study completion dates: Aug 2025 to Jun 2026 Start date: Mar 2022 to Jun 2022v3 Show 1 more changeShow less
    • Start date: Mar 2022 to Jun 2022
  2. Start date: Jan 2022 to Mar 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Trial Details
NCT Number NCT05196087
Lead Sponsor University Health Network, Toronto
Collaborators: Princess Margaret Hospital, Canada
Conditions Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
Enrollment 800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov